Inotuzumab ozogamicin
FDA Priority Review for Pfizer investigational leukaemia drug
February 22, 2017Research and Development, Sales and Marketing EMA, FDA, Inotuzumab ozogamicin, Pfizer, priority review
Pfizer has announced that its leukaemia treatment inotuzumab ozogamicin has been accepted for Priority Review by the US Food and …
Pfizer’s leukaemia drug beats chemotherapy in Phase III trials
June 13, 2016Research and Development, Sales and Marketing Inotuzumab ozogamicin, Pfizer, acute lymphoblastic leukaemia
Pfizer (NYSE: PFE) has announced data from a pivotal Phase III trial for acute lymphoblastic leukaemia (ALL) drug, inotuzumab ozogamicin, …
Two oncology successes for Pfizer
April 22, 2015Research and Development, Sales and Marketing Cancer, FDA, Inotuzumab ozogamicin, NSCLC, Pfizer, Xalkori, oncology
Pfizer has received two boosts in oncology as Xalkori gets a new breakthrough therapy designation from the FDA, and its …
Pfizer abandons cancer trial
May 22, 2013Research and Development, Sales and Marketing Cancer, Inotuzumab ozogamicin, Pfizer, oncology
Pfizer’s oncology pipeline has suffered a blow with the company abandoning a Phase III study of one of its investigational …
